Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay I Peters

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Drug Development and Industrial Pharmacy|September 18, 2008
Recent developments in drug delivery to prolong allograft survival in lung transplant patientsAlan B Watts, Robert O Williams, Jay I Peters
American Family Physician|May 14, 2016
Diagnosis and Management of SarcoidosisNatalia Soto-Gomez, Jay I Peters, Anoop M Nambiar
Respiratory Care|July 24, 2004
An assessment of the appropriateness of respiratory care delivered at a 450-bed acute care Veterans affairs hospitalDavid C Shelledy, Terry S LeGrand, Jay I Peters
Respiratory Care|May 6, 2005
Delivered oxygen concentrations using low-flow and high-flow nasal cannulasRichard B Wettstein, David C Shelledy, Jay I Peters
Therapeutic Delivery|July 27, 2012
Surfactants: their critical role in enhancing drug delivery to the lungsJavier O Morales, Jay I Peters, Robert O Williams
Plos One|April 26, 2017
Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosisAnoop M Nambiar, Antonio R Anzueto, Jay I Peters
International Journal of Pharmaceutics|December 25, 2012
Nebulization of mycophenolate mofetil inhalation suspension in rats: comparison with oral and pulmonary administration of Cellcept®Hélène L Dugas, Jay I Peters, Robert O Williams
International Journal of Pharmaceutics|January 15, 2011
Influence of particle size on regional lung deposition--what evidence is there?Thiago C Carvalho, Jay I Peters, Robert O Williams
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 28, 2013
Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective studyDiego Jose Maselli, Harjinder Singh, Joseph Diaz, et al.
International Journal of Pharmaceutics|December 3, 2013
The impact of pulmonary diseases on the fate of inhaled medicines--a reviewYi-Bo Wang, Alan B Watts, Jay I Peters, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Drug Development and Industrial Pharmacy|September 18, 2008
Recent developments in drug delivery to prolong allograft survival in lung transplant patientsAlan B Watts, Robert O Williams, Jay I Peters
American Family Physician|May 14, 2016
Diagnosis and Management of SarcoidosisNatalia Soto-Gomez, Jay I Peters, Anoop M Nambiar
Respiratory Care|July 24, 2004
An assessment of the appropriateness of respiratory care delivered at a 450-bed acute care Veterans affairs hospitalDavid C Shelledy, Terry S LeGrand, Jay I Peters
Respiratory Care|May 6, 2005
Delivered oxygen concentrations using low-flow and high-flow nasal cannulasRichard B Wettstein, David C Shelledy, Jay I Peters
Therapeutic Delivery|July 27, 2012
Surfactants: their critical role in enhancing drug delivery to the lungsJavier O Morales, Jay I Peters, Robert O Williams
Plos One|April 26, 2017
Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosisAnoop M Nambiar, Antonio R Anzueto, Jay I Peters
International Journal of Pharmaceutics|December 25, 2012
Nebulization of mycophenolate mofetil inhalation suspension in rats: comparison with oral and pulmonary administration of Cellcept®Hélène L Dugas, Jay I Peters, Robert O Williams
International Journal of Pharmaceutics|January 15, 2011
Influence of particle size on regional lung deposition--what evidence is there?Thiago C Carvalho, Jay I Peters, Robert O Williams
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 28, 2013
Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective studyDiego Jose Maselli, Harjinder Singh, Joseph Diaz, et al.
International Journal of Pharmaceutics|December 3, 2013
The impact of pulmonary diseases on the fate of inhaled medicines--a reviewYi-Bo Wang, Alan B Watts, Jay I Peters, et al.
Pageof 8